

Kryotherapie –Was kann diese Technik 2021?

Ulrich K. Fr. Witzsch

Literatur

- 1) Hoffmann NE, Bischof JC The Cryobiology of Cryosurgical Injury, *Urology* 2002, April; 60 (Suppl 2A): 40–49.
- 2) Gage AA, Baust J, Mechanisms of Tissue Injury in Cryosurgery, *Cryobiology* 1998; 37, 171–186.
- 3) Tatsutani F, Rubinsky B, Onik G, Dahiya R, Effect of Thermal Variables on Frozen Human Primary Prostatic Adenocarcinoma Cells, *Urology* 1996; 48: 441–447.
- 4) Larson T, Robertson D, Corica A, Bostwick D, In Vivo Interstitial Temperature Mapping of the Human Prostate during Cryosurgery with Correlation to Histopathological Outcomes, *Urology* 2000; 55: 547–552.
- 5) Patel B, Parsons C, Bidair M, Schmidt J, Cryoablation for Carcinoma of the Prostate, *Journal of Surgical Oncology* 1996; 63: 256–264.
- 6) Moore Y, Sofer P, Successful Treatment of Locally Confined Prostate Cancer with the Seed Net™ system – Preliminary multicenter results, *Clinical Application Notes*, 2001, June; 1–7.
- 7) Cytron S, Paz A, Kravchick S, Shumalinski D, Moore Y, Active Rectal Wall Protection Using Direct Transperitoneal Cryo-Needles for Histologically Proven Prostate Adenocarcinomas, *European Urology*, 2003; 44: 315–321.
- 8) Bahn DK, Lee F, Badalament R, Kumar A, Greski J, Chernick M. Targeted Cryoablation of the Prostate: 7-Year Outcomes in the Primary Treatment of Prostate Cancer, *Urology* 2002 (Suppl 2A) 60: 3–11.
- 9) Donnelly BJ, Saliken JC, Ernst DS, Ali-Ridha N, Brasher PM, Robinson JW, Rewcastle JC. Prospective Trial of Cryosurgical Ablation of the Prostate: Five-Year Results; *Urology*, 2002; 60: 645–649.
- 10) A. Zisman, A. Pantuck, J. Cohen, A. Belldegrun, Prostate Cryoablation using direct transperineal Placement of Ultrathin Probes through a 17- Gauge Brachytherapy Template-Technique and Preliminary Results, *Urology*, 2001; 58: 988–993.
- 11) J. Long, D. Bahn, F. Lee et al., Five-Year Retrospective, Multi-Institutional Pooled Analysis of Cancer-Related Outcomes after Cryosurgical Ablation of the Prostate, *Urology*, 2001; 57: 518–523.
- 12) Jeffrey K. Cohen, Cryosurgery of the Prostate: Techniques and Indications, *REVIEWS IN UROLOGY VOL. 6 SUPPL. 4* 2004; 520–526.
- 13) Aaron E, Katz MD, John C. Rewcastle, PhD. The Current and Potential Role of Cryoablation As a Primary Therapy for Localized Prostate Cancer , *Current Oncology Reports* 2003; 5: 231–238.
- 14) Erica H. Lambert, Kimberly Bolte, Puneet Masson and Aaron. E. Katz, Focal Cryosurgery: Encouraging health outcomes for unifocal Prostate Cancer, *Urology* 69 (6) 2007: 1117–1120.
- 15) Cytron, S., et al., Cryoablation of the Prostate: Technical Recommendations, *Prostate Cancer Prostatic Dis*, 2009; 12: 339–346.
- 16) EAU Guidelines update 2007.
- 17) Witzsch U, Dillenburg W, Poulakis V, Becht E, Kryotherapie des lokalisierten Prostatakarzinoms (PCA) mit Technologie der 3. Generation – Erfahrungen nach 4 Jahren, *Der Urologe (Suppl. 1)* 2006: 75.

- 18) Witzsch U, Dillenburg W, Hellwig W, Skriapas K, Sucke C, Becht E, Cryoablation of prostate cancer using 17 Gauge cryoneedles technology, 5 Year European Experience, *European Urology Supplements* 2007; 6: 201.
- 19) Witzsch U, Greene D, Bjerklund TE, Third Generation Cryosurgery for Prostate Cancer - European Experience, *Eur Urol Supplements* 2009; 8: 362.
- 20) Cohen J, Miller R, Ahmed S, Lotz M, Baust J, Ten-Year Biochemical Disease Control for Patients with Prostate Cancer Treated with Cryosurgery as Primary Therapy, *Urology*. 2008; 71: 515–518.
- 21) EAU Guidelines update 2009.
- 22) Prepelica K, Masson P, Benson MC, McKienan J, Katz AE, Salvagecryosurgical Ablation of the Prostate (TCAP) for patients failing radiation 10 year Experience, *AUA 2005* # 1662.
- 23) Ahmed S, Lindsay B, Davies J, Salvage cryosurgery for locally recurrent prostate cancer following radiotherapy, *prostate cancer and pediatric diseases* 2004: 1–5.
- 24) Witzsch UKFr, Skriapas K, Hieronymi S, Becht E, Salvage Cryoablation of prostate cancer using 17 Gauge cryoneedles technology 7 Year European Experience, *Eur Urol Supplements* 2009; 8: 361.
- 25) Hale Z, Miyake M, Palacios DA, Rosser CJ, Focal cryosurgical ablation of the prostate: a single institutes perspective, *BMC Urology* 2013: 13.
- 26) de Castro Abreu AL, Bahn D, Leslie S, Shoji S, Silverman P, Desai MM, et al. salvage focal and salvage total cryoablation for locally recurrent prostate cancer after primary radiation therapy, *BJU international* 2013; 112: 298–307.
- 27) Witzsch U, Hieronymi S, Voss G, Becht E. Salvage Cryoablation for Prostate cancer using 17 G Cryoneedles Technology is an local option after radical Prostatectomy failure (223) *Eur Urol Suppl* 2011; 10: 92.
- 28) Witzsch U, Greene D, Borre M, Bjerklund T: Salvage and primary 17G cryosurgery for prostate cancer - 10 year European experience (21) *Eur Urol Suppl* 2012; 11: 1.
- 29) Witzsch UKFr, Hieronymi S, Dillenburg W, Becht E. Outcome predictor after Cryoablation of prostate cancer using 17 gauge cryoneedles technology is the 3 Month posttherapy PSA level (983) *Eur Urol Suppl* 2012; 11:, 1.
- 30) D. Levy, A. Ross, A. El Shafei, N. Krishnan, A. Hatem, S. Jones, Definition of Biochemical Success Following Primary whole gland Prostate Cryoablation, *J.Urol* 192 p 1380–1384 2014.
- 31) Tan WP, Elshafei A, Aminsharifi A, Polascik T. Salvage focal cryotherapy offers similar short-term oncologic control and improved urinary function compared with salvage whole gland cryotherapy for radiation resistant/recurrent prostate cancer. 203, Supplement, 2020 MP70–12.
- 32) Donnelly BJ, Saliken JC, Brasher PM, Ernst SD, Rewcastle JC, Lau H, Robinson J, Trpkov K. A Randomized Trial of External Beam Radiotherapy VersusCryoablation in Patients with Localized Prostate Cancer, *Cancer*, 2010: 116; 323–330.
- 33) Shelley M, Wilt TJ, Coles B, Mason MD. Cryotherapy for Localised Prostate Cancer, *Cochrane Database Syst Rev*, 2007: CD005010.
- 34) Chin JL, Al-Zahrani AA, Autran-Gomez AM, Williams AK, Bauman G. Extended Followup Oncologic Outcome of Randomized Trial Between Cryoablation and External Beam Therapy for Locally Advanced Prostate Cancer (T2c-T3b), *J Urol*, 2012. 188: 1170–1175.